| Cell line name |
LR-BT474 |
|---|
| Accession |
CVCL_A2GH |
|---|
| Resource Identification Initiative |
To cite this cell line use: LR-BT474 (RRID:CVCL_A2GH) |
|---|
| Comments |
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Tyverb).
Omics: Transcriptome analysis by microarray.
Derived from site: In situ; Breast; UBERON=UBERON_0000310. |
|---|
| Sequence variations |
- Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line).
- Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line).
- Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line).
- Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line).
- Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line).
- Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Invasive breast carcinoma of no special type (NCIt: C4194) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0179 (BT-474) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
60Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=32942617; DOI=10.3390/cancers12092630; PMCID=PMC7564044
Lee H.J., Shin S., Kang J., Han K.-C., Kim Y.H., Bae J.-W., Park K.H.
HSP90 inhibitor, 17-DMAG, alone and in combination with lapatinib attenuates acquired lapatinib-resistance in ER-positive, HER2-overexpressing breast cancer cell line.
Cancers (Basel) 12:2630.1-2630.16(2020) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_A2GH
|
|---|
| Encyclopedic resources |
Wikidata; Q105509947
|
|---|
| Entry history |
|---|
| Entry creation | 12-Jan-2021 |
|---|
| Last entry update | 05-Oct-2023 |
|---|
| Version number | 5 |
|---|
